These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22547820)

  • 21. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.
    Marradi M; Di Gianvincenzo P; Enríquez-Navas PM; Martínez-Ávila OM; Chiodo F; Yuste E; Angulo J; Penadés S
    J Mol Biol; 2011 Jul; 410(5):798-810. PubMed ID: 21440555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.
    Gach JS; Furtmüller PG; Quendler H; Messner P; Wagner R; Katinger H; Kunert R
    J Biol Chem; 2010 Jan; 285(2):1122-7. PubMed ID: 19903812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
    Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
    Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.
    Doores KJ; Huber M; Le KM; Wang SK; Doyle-Cooper C; Cooper A; Pantophlet R; Wong CH; Nemazee D; Burton DR
    J Virol; 2013 Feb; 87(4):2234-41. PubMed ID: 23221565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissecting the carbohydrate specificity of the anti-HIV-1 2G12 antibody by single-molecule force spectroscopy.
    Martines E; García I; Marradi M; Padro D; Penadés S
    Langmuir; 2012 Dec; 28(51):17726-32. PubMed ID: 23198686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.
    Zhang H; Fu H; Luallen RJ; Liu B; Lee FH; Doms RW; Geng Y
    Vaccine; 2015 Sep; 33(39):5140-7. PubMed ID: 26277072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
    Chakrabarti BK; Walker LM; Guenaga JF; Ghobbeh A; Poignard P; Burton DR; Wyatt RT
    J Virol; 2011 Aug; 85(16):8217-26. PubMed ID: 21653673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.
    Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M
    J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STD NMR study of the interactions between antibody 2G12 and synthetic oligomannosides that mimic selected branches of gp120 glycans.
    Enríquez-Navas PM; Chiodo F; Marradi M; Angulo J; Penadés S
    Chembiochem; 2012 Jun; 13(9):1357-65. PubMed ID: 22628288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.